Cargando…
Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging
The everolimus–exemestane combination is indicated in advanced breast cancer treatment and usually well tolerated. The objective of the study was to determine the frequency of everolimus lung side effects and investigate their imaging characteristics on positron emission tomography with 18F-fluoro-d...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200531/ https://www.ncbi.nlm.nih.gov/pubmed/30290608 http://dx.doi.org/10.1097/MD.0000000000012518 |
_version_ | 1783365347208855552 |
---|---|
author | Dejust, Sebastien Morland, David Bruna-Muraille, Claire Eymard, Jean-Christophe Yazbek, Gabriel Savoye, Aude-Marie Papathanassiou, Dimitri |
author_facet | Dejust, Sebastien Morland, David Bruna-Muraille, Claire Eymard, Jean-Christophe Yazbek, Gabriel Savoye, Aude-Marie Papathanassiou, Dimitri |
author_sort | Dejust, Sebastien |
collection | PubMed |
description | The everolimus–exemestane combination is indicated in advanced breast cancer treatment and usually well tolerated. The objective of the study was to determine the frequency of everolimus lung side effects and investigate their imaging characteristics on positron emission tomography with 18F-fluoro-deoxy-glucose combined with computerized tomography ((18)F-FDG PET/CT). Our single-center retrospective descriptive study systematically included all patients with metastatic breast cancer treated by this combination (n = 29 representing 57 (18)F-FDG PET/CT). Number of segments involved was quantified. Maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), metabolic target volume (MTV), and total lesion glycolysis (TLG) were measured. Severe pneumopathy was studied by subgroup analysis. Pleuroparenchymal anomalies rate detected on (18)F-FDG PET/CT was 62%. Alveolar-interstitial lesions were mainly observed (89%) and affected 2.8 segments (0.5–11.5) with a median of 2 segments. S7 and S10 were the most involved segments with SUVmax 3.9 (1.3–8.8) and SUVmean 2.2 (0.7–4.9). Statistically significant difference (P = .02) was found with number of segment involved to characterize severe pneumopathy (average of 6.3 segments [2.5–11.5] vs 1.9 segments [0.5–8] for interstitial lung disease) but not with SUVmax, SUVmean, MTV, TLG (P = .14, 0.22, 0.22, and 0.17, respectively). The (18)F-FDG PET/CT could highlight pulmonary everolimus side effects, with a typical imaging pattern: alveolar-interstitial opacities associated with moderate uptake, more or less extensive, mainly affecting the lower lobes. Rarely, a pseudotumoral aspect may be detected, corresponding to a pitfall. MTV or TLG showed a tendency to differentiate severe pneumopathy vs interstitial lung disease but no statistically significant differences was observed contrarily to the number of segments involved. Further studies are necessary to determine if the (18)F-FDG PET/CT could early predict adverse effects of mTOR inhibitors. |
format | Online Article Text |
id | pubmed-6200531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-62005312018-11-07 Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging Dejust, Sebastien Morland, David Bruna-Muraille, Claire Eymard, Jean-Christophe Yazbek, Gabriel Savoye, Aude-Marie Papathanassiou, Dimitri Medicine (Baltimore) Research Article The everolimus–exemestane combination is indicated in advanced breast cancer treatment and usually well tolerated. The objective of the study was to determine the frequency of everolimus lung side effects and investigate their imaging characteristics on positron emission tomography with 18F-fluoro-deoxy-glucose combined with computerized tomography ((18)F-FDG PET/CT). Our single-center retrospective descriptive study systematically included all patients with metastatic breast cancer treated by this combination (n = 29 representing 57 (18)F-FDG PET/CT). Number of segments involved was quantified. Maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), metabolic target volume (MTV), and total lesion glycolysis (TLG) were measured. Severe pneumopathy was studied by subgroup analysis. Pleuroparenchymal anomalies rate detected on (18)F-FDG PET/CT was 62%. Alveolar-interstitial lesions were mainly observed (89%) and affected 2.8 segments (0.5–11.5) with a median of 2 segments. S7 and S10 were the most involved segments with SUVmax 3.9 (1.3–8.8) and SUVmean 2.2 (0.7–4.9). Statistically significant difference (P = .02) was found with number of segment involved to characterize severe pneumopathy (average of 6.3 segments [2.5–11.5] vs 1.9 segments [0.5–8] for interstitial lung disease) but not with SUVmax, SUVmean, MTV, TLG (P = .14, 0.22, 0.22, and 0.17, respectively). The (18)F-FDG PET/CT could highlight pulmonary everolimus side effects, with a typical imaging pattern: alveolar-interstitial opacities associated with moderate uptake, more or less extensive, mainly affecting the lower lobes. Rarely, a pseudotumoral aspect may be detected, corresponding to a pitfall. MTV or TLG showed a tendency to differentiate severe pneumopathy vs interstitial lung disease but no statistically significant differences was observed contrarily to the number of segments involved. Further studies are necessary to determine if the (18)F-FDG PET/CT could early predict adverse effects of mTOR inhibitors. Wolters Kluwer Health 2018-10-05 /pmc/articles/PMC6200531/ /pubmed/30290608 http://dx.doi.org/10.1097/MD.0000000000012518 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Dejust, Sebastien Morland, David Bruna-Muraille, Claire Eymard, Jean-Christophe Yazbek, Gabriel Savoye, Aude-Marie Papathanassiou, Dimitri Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging |
title | Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging |
title_full | Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging |
title_fullStr | Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging |
title_full_unstemmed | Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging |
title_short | Everolimus-induced pulmonary toxicity: Findings on (18)F-FDG PET/CT imaging |
title_sort | everolimus-induced pulmonary toxicity: findings on (18)f-fdg pet/ct imaging |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200531/ https://www.ncbi.nlm.nih.gov/pubmed/30290608 http://dx.doi.org/10.1097/MD.0000000000012518 |
work_keys_str_mv | AT dejustsebastien everolimusinducedpulmonarytoxicityfindingson18ffdgpetctimaging AT morlanddavid everolimusinducedpulmonarytoxicityfindingson18ffdgpetctimaging AT brunamurailleclaire everolimusinducedpulmonarytoxicityfindingson18ffdgpetctimaging AT eymardjeanchristophe everolimusinducedpulmonarytoxicityfindingson18ffdgpetctimaging AT yazbekgabriel everolimusinducedpulmonarytoxicityfindingson18ffdgpetctimaging AT savoyeaudemarie everolimusinducedpulmonarytoxicityfindingson18ffdgpetctimaging AT papathanassioudimitri everolimusinducedpulmonarytoxicityfindingson18ffdgpetctimaging |